Our top pick for
FibroGen Inc is a biotechnology business based in the US. FibroGen shares (FGEN) are listed on the NASDAQ and all prices are listed in US Dollars. FibroGen employs 599 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.75|
|52-week range||$9.88 - $57.21|
|50-day moving average||$11.14|
|200-day moving average||$18.23|
|Wall St. target price||$20.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-09)||N/A|
|1 month (2021-09-16)||-8.28%|
|3 months (2021-07-20)||-25.40%|
|6 months (2021-04-20)||-47.17%|
|1 year (2020-10-20)||-76.37%|
|2 years (2019-10-18)||-72.29%|
|3 years (2018-10-19)||52.9|
|5 years (2016-10-20)||17.65|
Valuing FibroGen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of FibroGen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
FibroGen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $49.3 million.
The EBITDA is a measure of a FibroGen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$171.8 million|
|Gross profit TTM||$-85,474,000|
|Return on assets TTM||-17.78%|
|Return on equity TTM||-66.58%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
There are currently 7.1 million FibroGen shares held short by investors – that's known as FibroGen's "short interest". This figure is 16.5% up from 6.1 million last month.
There are a few different ways that this level of interest in shorting FibroGen shares can be evaluated.
FibroGen's "short interest ratio" (SIR) is the quantity of FibroGen shares currently shorted divided by the average quantity of FibroGen shares traded daily (recently around 1.3 million). FibroGen's SIR currently stands at 5.37. In other words for every 100,000 FibroGen shares traded daily on the market, roughly 5370 shares are currently held short.
However FibroGen's short interest can also be evaluated against the total number of FibroGen shares, or, against the total number of tradable FibroGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case FibroGen's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 FibroGen shares in existence, roughly 80 shares are currently held short) or 0.0823% of the tradable shares (for every 100,000 tradable FibroGen shares, roughly 82 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against FibroGen.
Find out more about how you can short FibroGen stock.
We're not expecting FibroGen to pay a dividend over the next 12 months.
Over the last 12 months, FibroGen's shares have ranged in value from as little as $9.88 up to $57.2088. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while FibroGen's is 0.9852. This would suggest that FibroGen's shares are less volatile than average (for this exchange).
FibroGen, Inc. , a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.